Literature DB >> 24633743

Novel therapeutics in acute myeloid leukemia.

Kendra Sweet1, Jeffrey E Lancet.   

Abstract

Acute myeloid leukemia (AML) is a heterogenous disease, and the standard treatment with cytotoxic chemotherapy has remained largely unchanged for over four decades. As more is being learned about AML and the potential molecular targets found within the leukemia cells, an abundance of targeted therapies are becoming available for study in the treatment of this challenging disease. This review serves to provide a brief overview of some of several agents currently being studied and developed in AML.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24633743     DOI： 10.1007/s11899-014-0199-0

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  61 in total

1.  Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; B Douglas Smith; Mark J Levis; Steven D Gore; Jacqueline Greer; Catherine Hattenburg; Janet Briel; Richard J Jones; John J Wright; A Dimitri Colevas
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

3.  FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

Authors:  Amir T Fathi; Bruce A Chabner
Journal:  Oncologist       Date:  2011-07-17

Review 4.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Authors:  Guido Marcucci; Torsten Haferlach; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

5.  Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

Authors:  Courtney D DiNardo; Susan O'Brien; Varsha V Gandhi; Farhad Ravandi
Journal:  Future Oncol       Date:  2013-08       Impact factor: 3.404

6.  Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse.

Authors:  Lee-Yung Shih; Chein-Fuang Huang; Jin-Hou Wu; Tung-Liang Lin; Po Dunn; Po-Nan Wang; Ming-Chung Kuo; Chang-Liang Lai; Hui-Chin Hsu
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

7.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Amanda Blackford; B Douglas Smith; Katrina Alino; Amy Hatfield Seung; Javier Bolaños-Meade; Jacqueline M Greer; Hetty E Carraway; Steven D Gore; Richard J Jones; Mark J Levis; Michael A McDevitt; L Austin Doyle; John J Wright
Journal:  Leuk Res       Date:  2009-12-04       Impact factor: 3.156

9.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

10.  Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.

Authors:  David J Adams; Marit L Sandvold; Finn Myhren; Tove F Jacobsen; Frank Giles; David A Rizzieri
Journal:  Leuk Lymphoma       Date:  2008-04
View more
  8 in total

1.  Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.

Authors:  Stuart W Ember; Que T Lambert; Norbert Berndt; Steven Gunawan; Muhammad Ayaz; Marilena Tauro; Jin-Yi Zhu; Paula J Cranfill; Patricia Greninger; Conor C Lynch; Cyril H Benes; Harshani R Lawrence; Gary W Reuther; Nicholas J Lawrence; Ernst Schönbrunn
Journal:  Mol Cancer Ther       Date:  2017-03-23       Impact factor: 6.261

2.  The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Authors:  Taryn E Dick; Jeremy A Hengst; Todd E Fox; Ashley L Colledge; Vijay P Kale; Shen-Shu Sung; Arun Sharma; Shantu Amin; Thomas P Loughran; Mark Kester; Hong-Gang Wang; Jong K Yun
Journal:  J Pharmacol Exp Ther       Date:  2015-01-06       Impact factor: 4.030

Review 3.  Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.

Authors:  Nathan Gossai; Rachel Cafferty; Brenda Weigel
Journal:  Curr Treat Options Oncol       Date:  2016-07

4.  Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.

Authors:  Nianxi Zhao; Sung-Nan Pei; Jianjun Qi; Zihua Zeng; Swaminathan P Iyer; Pei Lin; Ching-Hsuan Tung; Youli Zu
Journal:  Biomaterials       Date:  2015-07-15       Impact factor: 12.479

5.  Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety.

Authors:  Xuan Zhao; Hang Zhong; Rui Wang; Dan Liu; Samuel Waxman; Linxiang Zhao; Yongkui Jing
Journal:  Oncotarget       Date:  2015-03-20

6.  Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.

Authors:  Li Gao; Junzhong Sun; Fang Liu; Hui Zhang; Yigai Ma
Journal:  Onco Targets Ther       Date:  2016-02-09       Impact factor: 4.147

7.  TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia.

Authors:  Hiroaki Ochiiwa; Guzhanuer Ailiken; Masataka Yokoyama; Kazuyuki Yamagata; Hidekazu Nagano; Chihoko Yoshimura; Hiromi Muraoka; Keiji Ishida; Tomonori Haruma; Akitoshi Nakayama; Naoko Hashimoto; Kazutaka Murata; Motoi Nishimura; Yusuke Kawashima; Osamu Ohara; Shuichi Ohkubo; Tomoaki Tanaka
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

8.  New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.

Authors:  Andreea Lucia Stancu; Mitchell R Smith; Alexandru Almasan
Journal:  Discoveries (Craiova)       Date:  2014 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.